[go: up one dir, main page]

SG11201605366QA - Pharmaceutical composition containing pyridylaminoacetic acidcompound - Google Patents

Pharmaceutical composition containing pyridylaminoacetic acidcompound

Info

Publication number
SG11201605366QA
SG11201605366QA SG11201605366QA SG11201605366QA SG11201605366QA SG 11201605366Q A SG11201605366Q A SG 11201605366QA SG 11201605366Q A SG11201605366Q A SG 11201605366QA SG 11201605366Q A SG11201605366Q A SG 11201605366QA SG 11201605366Q A SG11201605366Q A SG 11201605366QA
Authority
SG
Singapore
Prior art keywords
acidcompound
pharmaceutical composition
composition containing
pyridylaminoacetic
containing pyridylaminoacetic
Prior art date
Application number
SG11201605366QA
Inventor
Yoko Endo
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of SG11201605366QA publication Critical patent/SG11201605366QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11201605366QA 2014-01-10 2015-01-08 Pharmaceutical composition containing pyridylaminoacetic acidcompound SG11201605366QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014002810 2014-01-10
PCT/JP2015/050334 WO2015105135A1 (en) 2014-01-10 2015-01-08 Pharmaceutical composition containing pyridylamino acetic acid compound

Publications (1)

Publication Number Publication Date
SG11201605366QA true SG11201605366QA (en) 2016-08-30

Family

ID=53523960

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201605366QA SG11201605366QA (en) 2014-01-10 2015-01-08 Pharmaceutical composition containing pyridylaminoacetic acidcompound

Country Status (19)

Country Link
US (5) US10149908B2 (en)
EP (1) EP3093019B1 (en)
JP (1) JP6441087B2 (en)
KR (1) KR102281620B1 (en)
CN (1) CN105828818B (en)
AU (1) AU2015205179B2 (en)
BR (1) BR112016015909B1 (en)
CA (1) CA2935055C (en)
EA (1) EA031813B1 (en)
ES (1) ES2875307T3 (en)
GE (1) GEP20196982B (en)
IL (1) IL246655B (en)
MX (2) MX385505B (en)
MY (1) MY179951A (en)
PH (1) PH12016501328B1 (en)
SG (1) SG11201605366QA (en)
TW (1) TWI650127B (en)
UA (1) UA121746C2 (en)
WO (1) WO2015105135A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150279T1 (en) 2007-12-26 2015-05-08 Xencor, Inc. Fc variants with altered binding to fcrn
EP3424503B1 (en) * 2014-01-10 2020-09-02 Santen Pharmaceutical Co., Ltd Pharmaceutical preparation including pyridylamino acetic acid compound
CA2934612C (en) * 2014-01-10 2021-09-07 Santen Pharmaceutical Co., Ltd. Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
BR112016015909B1 (en) 2014-01-10 2020-09-29 Santen Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING PYRIDYLAMINOACETIC ACID COMPOUND
JP7032134B2 (en) 2015-07-09 2022-03-08 参天製薬株式会社 Prophylactic and / or therapeutic agents containing pyridylaminoacetic acid compounds
US20190038598A1 (en) * 2016-02-22 2019-02-07 Santen Pharmaceutical Co., Ltd. Pharmaceutical composition including dorzolamide and brimonidine
WO2018230713A1 (en) 2017-06-16 2018-12-20 学校法人同志社 Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent
CA3067332A1 (en) 2017-06-16 2018-12-20 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
JP7250685B2 (en) * 2017-09-29 2023-04-03 参天製薬株式会社 Medicine containing pyridylaminoacetic acid compound
WO2019124487A1 (en) 2017-12-21 2019-06-27 参天製薬株式会社 Omidenepag combination
EP3733179A4 (en) 2017-12-28 2021-09-15 Santen Pharmaceutical Co., Ltd. PHARMACEUTICAL PREPARATION WITH A PYRIDYLAMINOACETIC ACID

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
JP3297969B2 (en) 1994-12-26 2002-07-02 ライオン株式会社 Eye drops
EP0938896A1 (en) * 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent
ATE285795T1 (en) 1998-07-14 2005-01-15 Alcon Mfg Ltd POLYPROPYLENE BASED CONTAINERS FOR PROSTAGLANDIN CONTAINING PRODUCTS
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
US20020009507A1 (en) 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
JP2002356420A (en) * 2001-03-27 2002-12-13 Santen Pharmaceut Co Ltd Stable aqueous solution
JP5460996B2 (en) * 2007-10-19 2014-04-02 大正製薬株式会社 Ophthalmic agent
US8648097B2 (en) * 2008-03-12 2014-02-11 Ube Industries, Ltd. Pyridylaminoacetic acid compound
ES2564010T3 (en) * 2009-03-30 2016-03-17 Ube Industries, Ltd. Pharmaceutical composition to treat or prevent glaucoma
JP2011057633A (en) * 2009-09-11 2011-03-24 Ube Industries Ltd Medicine containing pyridylaminoacetic acid compound
JP2012180346A (en) * 2011-02-10 2012-09-20 Santen Pharmaceut Co Ltd Aqueous composition having improved drug migration property of hydrophilic drug
CA2830896A1 (en) 2011-04-12 2012-10-18 Yukihiko Mashima Aqueous ophthalmic composition
CN104136019A (en) * 2012-02-27 2014-11-05 日本乐敦制药株式会社 Ophthalmic Composition Kit
ES2702575T3 (en) 2012-03-26 2019-03-04 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol
WO2014010354A1 (en) 2012-07-09 2014-01-16 シャープ株式会社 Light emission device, illumination device, and insulating substrate
CA3099517C (en) 2012-07-13 2022-04-26 Santen Pharmaceutical Co., Ltd. Combinations comprising a sulfonamide compound for the treatment of glaucoma or ocular hypertension
US20140018350A1 (en) 2012-07-13 2014-01-16 Asahi Glass Co., Ltd. Combination of sulfonamide compound and tafluprost
JP2014019650A (en) * 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd Combination of sulfonamide compound and tafluprost
US9339496B2 (en) * 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
BR112016015909B1 (en) 2014-01-10 2020-09-29 Santen Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING PYRIDYLAMINOACETIC ACID COMPOUND
CA2934612C (en) * 2014-01-10 2021-09-07 Santen Pharmaceutical Co., Ltd. Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
EP3424503B1 (en) * 2014-01-10 2020-09-02 Santen Pharmaceutical Co., Ltd Pharmaceutical preparation including pyridylamino acetic acid compound

Also Published As

Publication number Publication date
AU2015205179B2 (en) 2019-09-19
US20240024484A1 (en) 2024-01-25
CN105828818B (en) 2020-06-02
KR102281620B1 (en) 2021-07-23
CA2935055A1 (en) 2015-07-16
US10149908B2 (en) 2018-12-11
US20190060459A1 (en) 2019-02-28
IL246655A0 (en) 2016-08-31
HK1224190A1 (en) 2017-08-18
EP3093019A1 (en) 2016-11-16
TW201609097A (en) 2016-03-16
US10765750B2 (en) 2020-09-08
MY179951A (en) 2020-11-19
US20200353084A1 (en) 2020-11-12
CN105828818A (en) 2016-08-03
NZ722144A (en) 2021-05-28
CA2935055C (en) 2021-08-24
MX385505B (en) 2025-03-18
EA201691244A1 (en) 2016-12-30
ES2875307T3 (en) 2021-11-10
US10485872B2 (en) 2019-11-26
JP2015147763A (en) 2015-08-20
IL246655B (en) 2020-05-31
TWI650127B (en) 2019-02-11
US20160317664A1 (en) 2016-11-03
PH12016501328B1 (en) 2020-07-01
MX2020003133A (en) 2021-08-23
UA121746C2 (en) 2020-07-27
PH12016501328A1 (en) 2017-02-06
EA031813B1 (en) 2019-02-28
US20200046839A1 (en) 2020-02-13
WO2015105135A1 (en) 2015-07-16
KR20160099582A (en) 2016-08-22
EP3093019B1 (en) 2021-05-26
AU2015205179A1 (en) 2016-07-28
BR112016015909B1 (en) 2020-09-29
GEP20196982B (en) 2019-06-25
EP3093019A4 (en) 2017-07-26
JP6441087B2 (en) 2018-12-19
MX2016009049A (en) 2016-09-09

Similar Documents

Publication Publication Date Title
IL282481A (en) Liquid pharmaceutical composition
GB201618482D0 (en) Pharmaceutical compositions
GB201419257D0 (en) Pharmaceutical compositions
IL277241A (en) Liquid pharmaceutical composition
GB201409471D0 (en) Pharmaceutical composition
IL249553A0 (en) Pharmaceutical compositions
IL249117A0 (en) Liquid pharmaceutical composition
SG11201605366QA (en) Pharmaceutical composition containing pyridylaminoacetic acidcompound
GB201409488D0 (en) Pharmaceutical composition
GB201409485D0 (en) Pharmaceutical composition
LT3278801T (en) Pharmaceutical composition containing mirabegron
ZA201508726B (en) Pharmaceutical composition
ZA201502073B (en) Pharmaceutical composition
IL250817A0 (en) Pharmaceutical compositions
ZA201700278B (en) Pharmaceutical composition containing docetaxel
SMT202000391T1 (en) Pharmaceutical composition
SG10201504332VA (en) Pharmaceutical Composition
SG11201608123VA (en) Pharmaceutical composition for external use
SG11201608124XA (en) Pharmaceutical composition for external use
SG11201608122PA (en) Pharmaceutical composition for external use
SG2014014872A (en) Pharmaceutical compositions
GB201408432D0 (en) Pharmaceutical compositions